Prospects and Challenges in the Development of Universal Influenza Vaccines

Madsen, Anders

doi:10.3390/vaccines8030361

Cited by 17 publications

(26 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mutations make the influenza viruses change over time. Hence, the genetic materials also change and new subtypes are evolved [ 45 ] which often replace the older strain [ 46 ]. It is a fact that influenza vaccines save countless lives and prevent pandemics but annual reformulation in vaccine preparation for the new emerging strains remains a challenge for the scientist [ 47 ].…”

Section: Main Textmentioning

confidence: 99%

Substantial effect of phytochemical constituents against the pandemic disease influenza—a review

Devi

Sarala

2021

Futur J Pharm Sci

View full text Add to dashboard Cite

Background Influenza is an acute respiratory tract infection caused by the influenza virus. Vaccination and antiviral drugs are the two methods opted to control the disease. Besides their efficiency, they also cause adverse side effects. Hence, scientists turned their attention to powerful herbal medicines. This review put focus on various proven, scientifically validated anti-influenza compounds produced by the plants suggested for the production of newer drugs for the better treatment of influenza and its related antiviral diseases too. Main body In this review, fifty medicinal herb phytochemical constituents and their anti-influenza activities have been documented. Specifically, this review brings out the accurate and substantiates mechanisms of action of these constituents. This study categorizes the phytochemical constituents into primary and secondary metabolites which provide a source for synthesizing and developing new drugs. Conclusion This article provides a summary of the actions of the herbal constituents. Since the mechanisms of action of the components are elucidated, the pandemic situation arising due to influenza and similar antiviral diseases can be handled promisingly with greater efficiency. However, clinical trials are in great demand. The formulation of usage may be a single drug compound or multi-herbal combination. These, in turn, open up a new arena for the pharmaceutical industries to develop innovative drugs.

show abstract

Section: Main Textmentioning

confidence: 99%

Substantial effect of phytochemical constituents against the pandemic disease influenza—a review

Devi

Sarala

2021

Futur J Pharm Sci

View full text Add to dashboard Cite

show abstract

“…UIVs are currently under development in laboratories worldwide. Dozens of research and review articles have been published in recent years by scientists from different countries all over the world [ 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ]. Calls to develop a highly effective universal influenza vaccine may be increased during the COVID-19 pandemic, due to the high potential for the co-circulation of two significant respiratory pathogens.…”

Section: Cross-protection Potency Of Influenza Vaccinesmentioning

confidence: 99%

New Points of Departure for More Global Influenza Vaccine Use

Kiseleva

2020

Vaccines

View full text Add to dashboard Cite

Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the drug resistance of currently circulating viruses reduce the effectiveness of prophylaxis and treatment and require the development of new broad-spectrum preparations. Furthermore, the challenge of creating a highly effective universal influenza vaccine takes on renewed intensity in the face of the COVID-19 pandemic.

show abstract

“…Moreover, usage of recombinant proteins as immunogens circumvents issues associated with alternative influenza vaccine production systems, such as the occurrence of adaptive mutations using embryonated hen eggs for virus growth [7]. For this reason, current under-development next generation influenza vaccines mostly rely on a recombinant protein-based platform [7,8]. Additionally, the here described protein production platform can be considered safer and more affordable as compared, for example, to transducing systems such as those relying on recombinant lentivirus [9].…”

Section: Introductionmentioning

confidence: 99%

High-Yield Expression and Purification of Recombinant Influenza Virus Proteins from Stably-Transfected Mammalian Cell Lines

et al. 2020

View full text Add to dashboard Cite

Influenza viruses infect millions of people each year, resulting in significant morbidity and mortality in the human population. Therefore, generation of a universal influenza virus vaccine is an urgent need and would greatly benefit public health. Recombinant protein technology is an established vaccine platform and has resulted in several commercially available vaccines. Herein, we describe the approach for developing stable transfected human cell lines for the expression of recombinant influenza virus hemagglutinin (HA) and recombinant influenza virus neuraminidase (NA) proteins for the purpose of in vitro and in vivo vaccine development. HA and NA are the main surface glycoproteins on influenza virions and the major antibody targets. The benefits for using recombinant proteins for in vitro and in vivo assays include the ease of use, high level of purity and the ability to scale-up production. This work provides guidelines on how to produce and purify recombinant proteins produced in mammalian cell lines through either transient transfection or generation of stable cell lines from plasmid creation through the isolation step via Immobilized Metal Affinity Chromatography (IMAC). Collectively, the establishment of this pipeline has facilitated large-scale production of recombinant HA and NA proteins to high purity and with consistent yields, including glycosylation patterns that are very similar to proteins produced in a human host.

show abstract

Prospects and Challenges in the Development of Universal Influenza Vaccines

Cited by 17 publications

References 96 publications

Substantial effect of phytochemical constituents against the pandemic disease influenza—a review

Substantial effect of phytochemical constituents against the pandemic disease influenza—a review

New Points of Departure for More Global Influenza Vaccine Use

High-Yield Expression and Purification of Recombinant Influenza Virus Proteins from Stably-Transfected Mammalian Cell Lines

Contact Info

Product

Resources

About